Showing results (1-10 of 134) with videos related to
Sort By:
Pageof 14
Science Immunology|November 7, 2020
Two mAbs take a stab at influenza's NActive siteMinh C Pham, Kevin C O'ConnorCell|April 9, 2025
Autoimmune mechanisms elucidated through muscle acetylcholine receptor structuresHuanhuan Li, Minh C Pham, Jinfeng Teng, et al.Neurology(R) Neuroimmunology & Neuroinflammation|July 18, 2025
AChR Autoantibody Pathogenic Properties Are Heterogeneously Distributed and Undergo Temporal Changes Among Patients With Myasthenia GravisFatemeh Khani-Habibabadi, Bhaskar Roy, Minh C Pham, et al.Journal of Neuroimmunology|April 2, 2022
The clinical need for clustered AChR cell-based assay testing of seronegative MGGianvito Masi, Yingkai Li, Tabitha Karatz, et al.JCI Insight|June 24, 2020
Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapsesRuoyi Jiang, Miriam L Fichtner, Kenneth B Hoehn, et al.Acta Neuropathologica|June 21, 2023
Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathologyMinh C Pham, Gianvito Masi, Rosa Patzina, et al.Journal of Neuroimmunology|September 15, 2024
Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathyLeah Baxter, Steven Hopkins, Kevin C O'Connor, et al.Annals of Clinical and Translational Neurology|March 16, 2023
Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravisGianvito Masi, Minh C Pham, Tabitha Karatz, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 4, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimodFatemeh Khani-Habibabadi, Fien M Verhamme, Mahan Moshir, et al.Pageof 14